Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


'Cures' vs Funding: FDA Appropriations Bill Is Latest Battleground

Executive Summary

The FDA policy reform debate just got more contentious.

You may also be interested in...

FDA Construction Plans Need 'Innovative Financing Options'

Senate Appropriations Committee says agency should look for alternatives to adding more space at its White Oak campus.

FDA Funding Debate Reframed By GAO Reports On Strategic Planning

Republican senators argue reports show that FDA needs significant reform; discussion of Cures and User Fee legislation will now likely focus on what the plan should be.

Orphan Designation Requests To Get Slower Reviews

FDA can't keep pace with requests, placing more pressure on sponsors to ensure submissions are complete.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts